Christopher S. Seet, MD, PhD, hematologist and oncologist, UCLA, discusses aspects of treatment discontinuation in chronic myeloid leukemia (CML).
Christopher S. Seet, MD, PhD
Advertisement
Articles by Christopher S. Seet, MD, PhD
Christopher S. Seet, MD, PhD, hematologist and oncologist, UCLA Health, discusses the need for long-term outcome data pertaining to treatment discontinuation in chronic myeloid leukemia (CML).
Advertisement
Latest Updated Articles
Dr. Seet on Aspects of Treatment Discontinuation in CMLSeptember 17th 2019
Advertisement
Advertisement
Trending on OncLive
1
HERIZON-GEA-01 PD-L1 Subgroup Data Support Zanidatamab Combo as a New Frontline SOC in HER2+ GEA
2
TALAPRO-3 Shows Talazoparib Plus Enzalutamide Improves rPFS in HRR-Altered mCSPC
3
Selinexor Plus Ruxolitinib Yields Superior Spleen Responses, OS Signal in JAK Inhibitor–Naïve Myelofibrosis
4
SERENA-6 Meets PFS2 End Point With Early Switch to Camizestrant in ER+/HER2-Negative, ESR1-Mutated Advanced Breast Cancer
5